Engrail Therapeutics

I have never used LinkedIn to share personal information but wanted to share some very tragic news with all of my colleagues, friends, and professional connections here. A few days ago my 16-year old daughter, Sarina, was tragically killed in an accident on a lake while on vacation in Illinois. My heroic son, Aric, helped retrieve her lifeless body from the water. Unfortunately, it was already too late. Sarina was a beacon of light - highly intelligent with a goofy sense of humor, a blossoming personality that featured empathy and open-mindedness, and quite possibly one of the most beautiful smiles on this planet. She clearly gained a lot from her mom! My family and friends didn't just lose our sweet Sarina...the world lost a wonderful human filled with potential to change the lives of so many. We laid her to rest not far from where she was born in Illinois yesterday. A memorial and permanent remembrance, spearheaded by her wonderful boyfriend and his family, will be held in California in the near future. Please consider supporting her memory here: https://gofund.me/4cd82d07 Please hug everyone a little tighter, love a little more, and practice kindness and forgiveness over ego, spite, and meanness. Life is too fragile and temporary. With love, Anil

Engrail Therapeutics’ VP of Translational Science and Clinical Development, Estibaliz Arce Cirauqui, shares her thoughts on recent breakthroughs and precompetitive initiatives that will be addressed at this year’s 𝟳𝘁𝗵 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 and sheds light on their lead program, a precision targeted GABA-A positive allosteric modulator for generalized anxiety disorder, which recently secured a $157 million Series B financing round. Estibaliz will be presenting on ‘𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗻𝗴 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗮𝗯𝗹𝗲 𝗜𝗺𝗮𝗴𝗲-𝗕𝗮𝘀𝗲𝗱 𝗧𝗼𝗼𝗹𝘀 𝘁𝗼 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗣𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗧𝗮𝗿𝗴𝗲𝘁𝘀’ at the upcoming summit. View the 3-day agenda here https://ter.li/l15nir for more information and secure your pass at the 𝗯𝗲𝘀𝘁 𝗿𝗮𝘁𝗲 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 here https://ter.li/131e9t before 𝗲𝗮𝗿𝗹𝘆 𝗯𝗶𝗿𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗲𝘅𝗽𝗶𝗿𝗲 𝘁𝗵𝗶𝘀 𝗙𝗿𝗶𝗱𝗮𝘆 𝗠𝗮𝘆 𝟯𝟭!

#Anxiety is an epidemic. According to World Health Organization (#WHO) estimates, anxiety affects more than 300 million people worldwide and is the most common of all mental health disorders.   Despite the prevalence and impact of anxiety, there is a lack of effective, non-habit-forming medicine for treating chronic anxiety disorders. RiverVest portfolio company Engrail Therapeutics is working to address that high unmet need.   During Mental Health Awareness month, we spoke with Vikram Sudarsan, Ph.D., founder and CEO of Engrail, about the prevalence of anxiety disorders, the challenges in treating them, and the potential for the company’s novel drug therapeutic ENX-102 now in a Phase 2 clinical study for treating generalized anxiety disorder (#GAD).   Read RiverVest's latest Expert Insight to learn about Engrail Therapeutics and ENX-102, a positive allosteric modulator that selectively targets specific subunits of the GABA receptor to overcome the side-effects posed by benzodiazepines while maintaining efficacy that SSRIs and SNRIs are unable to achieve.   Engrail is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience. Its purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases. In March 2024, the company closed on an oversubscribed $157 million Series B financing round co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn, Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, Engrail has raised over $220 million. Niall O'Donnell Isaac Zike Ph.D. Anil Vootkur #mentalhealth #MentalHealthAwarenessMonth #generalizedanxietydisorder #benzodiazepines #SSRIs #neuroscience #anxiety #neuropsychiatry

#Anxiety is an epidemic. According to World Health Organization (#WHO) estimates, anxiety affects more than 300 million people worldwide and is the most common of all mental health disorders.   Despite the prevalence and impact of anxiety, there is a lack of effective, non-habit-forming medicine for treating chronic anxiety disorders. RiverVest portfolio company Engrail Therapeutics is working to address that high unmet need.   During Mental Health Awareness month, we spoke with Vikram Sudarsan, Ph.D., founder and CEO of Engrail, about the prevalence of anxiety disorders, the challenges in treating them, and the potential for the company’s novel drug therapeutic ENX-102 now in a Phase 2 clinical study for treating generalized anxiety disorder (#GAD).   Read RiverVest's latest Expert Insight to learn about Engrail Therapeutics and ENX-102, a positive allosteric modulator that selectively targets specific subunits of the GABA receptor to overcome the side-effects posed by benzodiazepines while maintaining efficacy that SSRIs and SNRIs are unable to achieve.   Engrail is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience. Its purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases. In March 2024, the company closed on an oversubscribed $157 million Series B financing round co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn, Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, Engrail has raised over $220 million. Niall O'Donnell Isaac Zike Ph.D. Anil Vootkur #mentalhealth #MentalHealthAwarenessMonth #generalizedanxietydisorder #benzodiazepines #SSRIs #neuroscience #anxiety #neuropsychiatry

We recently announced our investment in Engrail Therapeutics and are thrilled to partner with Vikram Sudarsan, building on an old and successful relationship from our Cipla Health Ltd investment, as he and his team are developing innovative therapies for neuropsychiatric disorders. Here are some thoughts from Siyu Shi, MD and myself on what makes this super exciting! #healthcare #therapeutics #drugdiscovery #innovation #startup Kimberly Vanover Camilla Gomiero Wade Anil Vootkur Prem Pavoor Ketan Patel Stacie Weninger Engrail Therapeutics F-Prime Capital Eight Roads